Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR   US00484M1062

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2015 03/23/2015 03/24/2015 03/25/2015 03/26/2015 Date
34.74(c) 34.72(c) 34.76(c) 33.63(c) 32.94(c) Last
1 032 955 518 728 700 302 946 449 611 781 Volume
-1.11% -0.06% +0.12% -3.25% -2.05% Change
More quotes
Financials ($)
Sales 2015 454 M
EBIT 2015 1,95 M
Net income 2015 -22,4 M
Finance 2015 25,5 M
Yield 2015 -
Sales 2016 513 M
EBIT 2016 40,5 M
Net income 2016 -12,4 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 3,03x
Capi. / Sales 2016 2,73x
Capitalization 1 402 M
More Financials
Company
Acorda Therapeutics, Inc. engages in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the nervous system.The company's two main products are Ampyra and Zanaflex... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
03/25 ACORDA THERAPEUTICS : Rings NASDAQ Opening Bell to Mark 20th Anniversary
03/18 ACORDA THERAPEUTICS : to Present New Analyses of Cimaglermin alfa GGF2 Data at t..
03/16 ACORDA THERAPEUTICS : Rings NASDAQ Opening Bell to Mark 20th Anniversary
03/14 ACORDA THERAPEUTICS : ACOR) to Ring The Nasdaq Stock Market Opening Bell
03/13 ACORDA THERAPEUTICS : to Release New Analyses of Cimaglermin alfa Data
03/12 ACORDA THERAPEUTICS : Scanning Biotech Equities -- Agenus, Amicus Therapeutics, ..
03/10 ACORDA THERAPEUTICS : to Present New Analyses of Cimaglermin alfa (GGF2) Data at..
03/04 ACORDA THERAPEUTICS : Mayo Foundation for Medical Education & Research, Acorda T..
More news
Sector news : Bio Therapeutic Drugs
08:36a ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/26 Alliance invokes Elliott track record in appeal against board shake-up
03/26 ACTELION : receives marketing approval for Opsumit (macitentan) in pulmonary art..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/25 NEW PATENT LEGISLATION : Impacts On Publicly-Traded Patent Investments
03/18 Not In Favor Of The Solar Industry - Cramer's Lightning Round (3/17/15)
02/26 New Parkinson's drug cleared in Europe
02/24 ACORDA 2015 : Patents, Pipeline And Patients; Cash And Catalysts
02/24 ACORDA THERAPEUTICS : 2015 Growth Estimates Are Fair


Comments 
Advertisement
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF